// startup autopsy

Aciex Therapeutics

Ophthalmic drug developer absorbed by Nicox before its pipeline could reach the market

acquisition gone wrongAcqui-hire

Fatal mistake: Insufficient capital to advance ophthalmic pipeline through Phase 3 trials independently, forcing an early acquisition before full value could be realized.

Founded	2008
Closed	2014
Country	USA
Sector	Biotech

50%

Key Events Timeline

2008-01-01

FOUNDING

Aciex Therapeutics founded in the USA to develop specialty ophthalmic pharmaceutical products for dry eye and allergic eye conditions.

2011-06-01

FUNDING

Raised early funding to advance lead ophthalmic compounds through Phase 2 clinical trials.

2013-09-01

PRODUCT LAUNCH

Initiated Phase 2 clinical trials for lead dry eye compound, showing promising early efficacy data.

2014-03-01

FUNDING

Secured final funding round totaling ~$9.6M as the company explored strategic partnerships and acquisition options.

2014-10-01

SHUTDOWN

Nicox completed acquisition of Aciex Therapeutics, ending independent operations and absorbing the ophthalmic pipeline.

Full Analysis

Analyst plan

Documented cause

Aciex Therapeutics, a USA-based biotech company focused on ophthalmic drugs for dry eye disease and allergic conjunctivitis, failed as an independent entity through an acqui-hire in 2014. After raising approxim...

ately $9.6 million in funding, the company was acquired by Nicox, a larger ophthalmic pharmaceutical company. This acquisition represented a failure of Aciex's independent operations, as the acqui-hir

Verified lesson

“...”

Unlock full lesson →

€17.3M

Peak valuation

HypeCycle · MoatType · ResearchTags

Aciex Therapeutics raised €9.59986M before insufficient capital to advance ophthalmic pipeline through phase 3 trials independently, forcing an early acquisition before full value could be realized. ended it. See the documented cause, verified lesson and all failure signals.

Unlock full analysis →Create free account

See all plans·Analyst plan — €149/mo